Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 19 Feb 2018 Planned End Date changed from 1 Jan 2024 to 1 Jul 2024.
- 19 Feb 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Apr 2019.
- 19 Feb 2018 Status changed from not yet recruiting to recruiting.